SXTP: Q2 revenue doubled year-over-year, but losses and cash burn raise going concern risks
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw a 106% year-over-year increase in product revenue, but gross margin declined to 27.3% due to higher costs. Operating expenses rose 25%, and the company reported a net loss of $2.26 million, with cash runway projected only through early October 2026.Original document: 60 Degrees Pharmaceuticals, Inc. [SXTP] SEC 10-Q Quarterly Report — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw a 106% year-over-year increase in product revenue, but gross margin declined to 27.3% due to higher costs. Operating expenses rose 25%, and the company reported a net loss of $2.26 million, with cash runway projected only through early October 2026.
Original document: 60 Degrees Pharmaceuticals, Inc. [SXTP] SEC 10-Q Quarterly Report — Aug. 14 2026